Rory Smoot retweeted
In this paper in press, we demonstrate a dual role of TRAIL-TRAIL-R in #CCA
👉🏼 Noncanonical TRAIL signaling augments MDSC abundance
👉🏼 Canonical TRAIL signaling promotes CCA cell apoptosis but is less potent
👉🏼MDSC are resistant to TRAIL-induced apoptosis bit.ly/449CnL9
Study finds noncanonical TRAIL signaling promotes myeloid-derived suppressor cell abundance and tumor growth in #cholangiocarcinoma. 🌟 Learn more at ow.ly/q8nG50Ri9ra
Fantastic presentation by Dr. Jennifer Tomlinson, a talented surgery resident, at the Cholangiocarcinoma Foundation Meeting highlighting her work on targeting TEADs.
Rory Smoot retweeted
The inaugural Basic science track day at the @curecc Annual Conference is off to a great start. Fantastic first session with remarkable speakers and robust discussion focused on nanoparticles, adoptive cell therapy, innovative models, and CCA multiomics. @siadaniela @LesinskiLab
Excited to share some our latest research. doi.org/10.1093/pnasnexus/pg…
Rory Smoot retweeted
It’s Cholangiocarcinoma Awareness month. Our growing #CCA discovery science team celebrated #WorldCCADAY. 5 teams under one #CCA umbrella all with one mission: to improve outcomes for our CCA patients. #greenforCCA @curecc
Rory Smoot retweeted
Happy to see friends and mentees teaming up to produce a nice piece.
This Post is from an account that no longer exists. Learn more
Post doctoral fellow Dr. Shohei Takaichi presenting his work unraveling resistance mechanisms in #cholangiocarcinoma at #AACR2023. @curecc @MayoClinicSurg @MayoCancerCare
Another great contribution from the Guggenheim 17 family. #Senescence in cholangiocytes via ETS1. #PSC @NFLaRussoMD @MedCityGirl @MayoClinicGIHep gastrojournal.org/article/S0…
2
249
Rory Smoot retweeted
New @TheLancet - Kelley et al - Pembrolizumab plus gemcitabine and cisplatin vs gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966)
thelancet.com/journals/lance…
#gitwitter #onctwitter
A talented research technician from my group, Danielle Carlson, presenting our data on targeting hsf1 activity in #cholangiocarcinoma patient-derived xenografts. #aacr2023 @curecc @MayoClinicSurg @MayoCancerCare
Dr. Tomlinson presenting our work with aptamer targeted RNA therapeutics for #cholangiocarcinoma #AACR2023 @curecc @MayoClinicSurg @MayoCancerCare
Rory Smoot retweeted
1/3🚀JHEP Twittorial🚀
☘️A step forward for targeting Hippo pathway in CCA
🔓👉https://xitter.cf/t.co/fqfe91JyFo
CCAs 👉⬆️activity of oncogenic LCK (Src family tyrosine kinase)/YAP (Yes-associated protein) dependent Hippo path
Hippo💊👉challenge
Rory L. Smoot & cols👇👇
#livertwitter
















